您的购物车当前为空
别名 非拉司特, SB 683699
Firategrast (SB 683699) 是一种具有口服活性和特异性的α4β1/α4β7整合素拮抗剂。Firategrast 减少淋巴细胞进入中枢神经系统 (CNS) 的运输,降低多发性硬化症 (MS) 的活性。Firategrast 用于复发缓解性多发性硬化症。Firategrast 治疗与中位脑脊液与 CD4,CD8和CD19淋巴细胞计数的适度降低有关。


为众多的药物研发团队赋能,
让新药发现更简单!
Firategrast (SB 683699) 是一种具有口服活性和特异性的α4β1/α4β7整合素拮抗剂。Firategrast 减少淋巴细胞进入中枢神经系统 (CNS) 的运输,降低多发性硬化症 (MS) 的活性。Firategrast 用于复发缓解性多发性硬化症。Firategrast 治疗与中位脑脊液与 CD4,CD8和CD19淋巴细胞计数的适度降低有关。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 328 | In stock | |
| 5 mg | ¥ 828 | In stock | |
| 10 mg | ¥ 1,320 | In stock | |
| 25 mg | ¥ 2,880 | In stock | |
| 50 mg | ¥ 4,630 | In stock | |
| 100 mg | ¥ 6,490 | In stock | |
| 200 mg | ¥ 8,750 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 892 | In stock |
Firategrast 相关产品
| 产品描述 | Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist.Firategrast reduces the transport of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.Firategrast is used in relapsing-remitting multiple sclerosis.Firategrast treatment is associated with a median cerebrospinal fluid associated with modest reductions in CD4, CD8, and CD19 lymphocyte counts. |
| 靶点活性 | α4β1 (VLA-4):198 nM |
| 体外活性 | Firategrast 抑制了可溶性VCAM/Fc嵌合蛋白(sVCAM-1)与G2急性淋巴细胞白血病(ALL)细胞的结合。此外,Firategrast(0.1-10 µM; 1小时)显著减少了慢性淋巴细胞性白血病(CLL)细胞的粘附力。 |
| 体内活性 | Firategrast以每日30mg/kg的剂量通过饮用水给药,自移植后2日或7日开始,持续21天。此治疗显著减少了脾脏中的白血病细胞。[4] |
| 别名 | 非拉司特, SB 683699 |
| 分子量 | 499.5 |
| 分子式 | C27H27F2NO6 |
| CAS No. | 402567-16-2 |
| Smiles | CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1 |
| 密度 | 1.261 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 90 mg/mL (180.18 mM), Sonication is recommended. Ethanol: 45 mg/mL (90.09 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
评论内容